Between Informality and Organized Crime: Criminalization of Small-Scale Mining in the Peruvian Rainforest

“Mining, like other types of resource extraction, is often carried out by a number of actors ranging from licit to illicit. Laws governing resource extraction have to balance the interests of the local economy, the environment, and law enforcement. In Peru, the government has attempted to tackle the increasing involvement of organized crime groups (OCGs) in the jungle region of Madre de Dios by placing “illegal mining” under the organized crime legislation, thereby elevating the seriousness of illegal mining to an activity classified as “organized crime.” This chapter studies the implications of this classification in the local context of Madre de Dios, focusing on the impact this legislative change is having on the local population involved in artisanal and small-scale gold mining (ASGM). Ethnographic fieldwork and qualitative interviews reveal how conflicting policies have erased the line between the informal and the illegal, victimizing those local miners willing to make the step toward environmental sustainability through the formalization process

The Diversification of Organized Crime into Gold Mining: Domination, Crime Convergence, and Ecocide in Darién, Colombia

“Gold mining has become a significant new form of organized crime activity in Colombia, where criminal groups continue to shift their operations from cocaine trafficking into gold mining. This chapter focuses on how the Gulf Clan has diversified into gold mining in Colombia, why gold extraction is embedded in other organized crime activities, and how diversification accelerates ecocide. By positioning theoretical concepts within the environmental crime continuum and reflected on the ecocidal harms related to gold production, this chapter contributes to organized crime theory and green criminology. The empirical findings presented in this chapter are based on fieldwork carried out in Colombia’s Darién jungle between 2017 and 2019. The information gathered shows how the Gulf Clan transformed their features in order to diversify into the gold business. Key issues discussed include the legal-illegal interface, the role of social embeddedness, and how the local communities are impacted by ecocidal harms

Green Criminology and Native Peoples: The Treadmill of Production and the Killing of Indigenous Environmental Activists

During the development of green criminology, little attention has been paid to how Indigenous/Native Peoples (INP) are victimized by green crime and how they employ environmental activism to resist externally imposed ecological destruction. In the past decade, news services and environmental interest groups have reported on the killing of INP environmental activists who have resisted ecological destruction across the world. Here, we begin to develop a green criminological view of INP victimization and resistance to ecological destruction within the context of the global capitalist treadmill of production, while drawing upon concepts of colonization, imperialism, genocide and ecocide. Our analysis suggests that in the contemporary capitalist world system, expansion of the treadmill of production’s ecological withdrawal process (i.e. the withdrawal of raw materials used in production) not only accelerates ecological disorganization in developing/underdeveloped nations, but may be harmful in nations where INP are dependent on access to nature for survival

Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients

Bococizumab is a humanized monoclonal antibody that inhibits proprotein convertase subtilisin- kexin type 9 (PCSK9) and reduces levels of low-density lipoprotein (LDL) cholesterol. We sought to evaluate the efficacy of bococizumab in patients at high cardiovascular risk. METHODS In two parallel, multinational trials with different entry criteria for LDL cholesterol levels, we randomly assigned the 27,438 patients in the combined trials to receive bococizumab (at a dose of 150 mg) subcutaneously every 2 weeks or placebo. The primary end point was nonfatal myocardial infarction, nonfatal stroke, hospitalization for unstable angina requiring urgent revascularization, or cardiovascular death; 93% of the patients were receiving statin therapy at baseline. The trials were stopped early after the sponsor elected to discontinue the development of bococizumab owing in part to the development of high rates of antidrug antibodies, as seen in data from other studies in the program. The median follow-up was 10 months. RESULTS At 14 weeks, patients in the combined trials had a mean change from baseline in LDL cholesterol levels of -56.0% in the bococizumab group and +2.9% in the placebo group, for a between-group difference of -59.0 percentage points (P<0.001) and a median reduction from baseline of 64.2% (P<0.001). In the lower-risk, shorter-duration trial (in which the patients had a baseline LDL cholesterol level of ≥70 mg per deciliter [1.8 mmol per liter] and the median follow-up was 7 months), major cardiovascular events occurred in 173 patients each in the bococizumab group and the placebo group (hazard ratio, 0.99; 95% confidence interval [CI], 0.80 to 1.22; P = 0.94). In the higher-risk, longer-duration trial (in which the patients had a baseline LDL cholesterol level of ≥100 mg per deciliter [2.6 mmol per liter] and the median follow-up was 12 months), major cardiovascular events occurred in 179 and 224 patients, respectively (hazard ratio, 0.79; 95% CI, 0.65 to 0.97; P = 0.02). The hazard ratio for the primary end point in the combined trials was 0.88 (95% CI, 0.76 to 1.02; P = 0.08). Injection-site reactions were more common in the bococizumab group than in the placebo group (10.4% vs. 1.3%, P<0.001). CONCLUSIONS In two randomized trials comparing the PCSK9 inhibitor bococizumab with placebo, bococizumab had no benefit with respect to major adverse cardiovascular events in the trial involving lower-risk patients but did have a significant benefit in the trial involving higher-risk patients